Sugi Predict

Sugi Predict / Compounds / SCHEMBL1029643

SCHEMBL1029643

SCHEMBL1029643

CC(=O)Nc1ccc(F)cc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.55
▸ HPGD P15428 1/20 0.55
▸ MAPT P10636 4/20 0.54
▸ LMNA P02545 2/20 0.52
▸ KDM4E B2RXH2 2/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ HTT P42858 2/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ HDAC1 Q13547 2/20 0.48
▸ HDAC3 O15379 1/20 0.48
▸ HDAC2 Q92769 1/20 0.48
▸ NCOR2 Q9Y618 1/20 0.48
▸ ESR1 P03372 1/20 0.48
▸ HDAC6 Q9UBN7 1/20 0.47
▸ POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1887376 0.85 KMT2A (0.59) ALDH1A1HPGDMAPTLMNAKDM4E
SCHEMBL15296458 0.83 ALDH1A1 (0.52) ALDH1A1MAPTLMNAKDM4ESMN1; SMN2
SCHEMBL28265144 0.83 ALDH1A1 (0.52) ALDH1A1MAPTLMNAKDM4ESMN1; SMN2
SCHEMBL19462130 0.83 HDAC1 (0.73) ALDH1A1MAPTLMNAKDM4ESMN1; SMN2
SCHEMBL6694651 0.82 SMN1; SMN2 (0.67) ALDH1A1MAPTKDM4ESMN1; SMN2NPC1
SCHEMBL30148008 0.82 SMN1; SMN2 (0.67) ALDH1A1MAPTKDM4ESMN1; SMN2NPC1
SCHEMBL15708434 0.81 ALDH1A1 (0.61) ALDH1A1MAPTLMNAKDM4ESMN1; SMN2
SCHEMBL9979393 0.81 CYP1A2 (0.55) ALDH1A1HPGDMAPTLMNAKDM4E
SCHEMBL11406833 0.81 ALDH1A1 (0.54) ALDH1A1MAPTLMNAKDM4ESMN1; SMN2
SCHEMBL15708436 0.81 ALDH1A1 (0.61) ALDH1A1MAPTLMNAKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-02-20 — — US disclosed
CN-114555555-B Process for preparing 1,1' -disulfanediylbis (4-fluoro-2-methyl-5-nitrobenzene) 拜耳公司 2024-03-01 — — CN disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 — — US disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 — — US disclosed
US-11629134-B2 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2023-04-18 — — US disclosed
US-11548892-B1 Transglutaminase 2 (TG2) inhibitors SITARI PHARMA, INC. (US) 2023-01-10 — — US disclosed
US-20220348538-A1 PROCESS OF PREPARING 1,1'-DISULFANDIYLBIS(4-FLUORO-2-METHYL-5-NITROBENZOL) BAYER AKTIENGESELLSCHAFT (DE) 2022-11-03 — — US disclosed
US-20220348538-A1 PROCESS OF PREPARING 1,1'-DISULFANDIYLBIS(4-FLUORO-2-METHYL-5-NITROBENZOL) BAYER AKTIENGESELLSCHAFT (DE) 2022-11-03 — — US disclosed
EP-4045482-A1 PROCESS OF PREPARING 1,1'-DISULFANDIYLBIS(4-FLUORO-2-METHYL-5-NITROBENZOL) Bayer Aktiengesellschaft (DE) 2022-08-24 — — EP disclosed
CN-108699032-B Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders 默克专利有限公司 2022-07-22 — — CN disclosed
EP-1932837-A1 BICYCLO HETEROCYCLIC COMPOUND HAVING ANTIFUNGAL ACTION Daiichi Sankyo Company, Limited (JP) 2008-06-18 — — EP disclosed
EP-1156044-B1 6-SUBSTITUTED HETEROQUINOLINECARBOXYLIC ACID DERIVATIVES AND ADDITION SALTS THEREOF AND PROCESSES FOR THE PREPARATION OF BOTH KYORIN SEIYAKU KK (JP) 2004-08-25 — — EP disclosed
US-6562839-B1 Effective for the therapy of disorder of cerebral nerve cells as antagonists against excitatory amino acid receptors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2003-05-13 — — US disclosed
EP-1216226-A2 PROCESS FOR PHENYLACETIC ACID DERIVATIVES Novartis AG (CH) 2002-06-26 — — EP disclosed
EP-1156044-A1 6-SUBSTITUTED HETEROQUINOLINECARBOXYLIC ACID DERIVATIVES AND ADDITION SALTS THEREOF AND PROCESSES FOR THE PREPARATION OF BOTH KYORIN PHARMACEUTICAL CO., LTD. (JP) 2001-11-21 — — EP disclosed
WO-2001023346-A2 PROCESS FOR PHENYLACETIC ACID DERIVATIVES NOVARTIS AG (CH) 2001-04-05 — — WO disclosed
WO-1993012795-A1 QUINAZOLIN-4(3H)-ONE DERIVATIVES AS ANTICOCCIDIAL AGENTS GLAZER EDWARD A (US) 1993-07-08 — — WO disclosed
US-4920224-A CHEMICAL INTERMEDIATES PFIZER INC. (US) 1990-04-24 — — US disclosed
US-4849518-A ANTIPROTOZOA IN POULTRY PFIZER INC. (US) 1989-07-18 — — US disclosed
US-4762838-A Quinazolin-4(3H)-one derivatives as anticoccidial agents PFIZER INC. (US) 1988-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 ALDH1A1 2648/4885HPGD 3856/4885MAPT 4219/4885
US-11548892-B1 Transglutaminase 2 (TG2) inhibitors TGM2, TGM3, TGM1 ALDH1A1 4148/4885HPGD 944/4885MAPT 353/4885
US-11629134-B2 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 ALDH1A1 2648/4885HPGD 3856/4885MAPT 4219/4885
US-20220348538-A1 PROCESS OF PREPARING 1,1'-DISULFANDIYLBIS(4-FLUORO-2-METHYL-5-NITROBENZOL) DDT, PFAS, DNPH1 ALDH1A1 223/4885HPGD 1466/4885MAPT 4097/4885
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 ALDH1A1 2648/4885HPGD 3856/4885MAPT 4219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.